|Bid||7,855.00 x 0|
|Ask||7,856.00 x 0|
|Day's range||7,791.00 - 7,889.23|
|52-week range||5,871.00 - 10,120.00|
|Beta (5Y monthly)||0.22|
|PE ratio (TTM)||48.00|
|Earnings date||05 Nov 2020|
|Forward dividend & yield||2.16 (2.73%)|
|Ex-dividend date||13 Aug 2020|
|1y target est||78.83|
Newest wave of coronavirus could be controlled with better leadership, U.S. experts say.
The fatality is the latest setback for AZD1222, developed in coordination with the University of Oxford.
U.S. phase 3 studies for AstraZeneca's and Johnson & Johnson's coronavirus vaccines still haven't resumed. Should investors be worried?